701 HOST GENETIC DETERMINANTS IN HCV-RELATED MIXED CRYOGLOBULINEMIA

2010 ◽  
Vol 52 ◽  
pp. S272-S273
Author(s):  
A. Piluso ◽  
L. Gragnani ◽  
P. Caini ◽  
E. Fognani ◽  
C. Giannini ◽  
...  
2010 ◽  
Vol 42 ◽  
pp. S4
Author(s):  
L. Gragnani ◽  
A. Piluso ◽  
P. Caini ◽  
E. Fognani ◽  
C. Giannini ◽  
...  

2011 ◽  
Vol 63 (5) ◽  
pp. 1446-1451 ◽  
Author(s):  
Laura Gragnani ◽  
Alessia Piluso ◽  
Carlo Giannini ◽  
Patrizio Caini ◽  
Elisa Fognani ◽  
...  

2015 ◽  
Vol 6 (1) ◽  
Author(s):  
Adam J. Dobson ◽  
John M. Chaston ◽  
Peter D. Newell ◽  
Leanne Donahue ◽  
Sara L. Hermann ◽  
...  

2011 ◽  
Vol 203 (6) ◽  
pp. 773-779 ◽  
Author(s):  
Jacques Fellay ◽  
Nicole Frahm ◽  
Kevin V. Shianna ◽  
Elizabeth T. Cirulli ◽  
Danilo R. Casimiro ◽  
...  

Blood ◽  
1998 ◽  
Vol 91 (6) ◽  
pp. 2062-2066 ◽  
Author(s):  
Marco Lenzi ◽  
Magda Frisoni ◽  
Vilma Mantovani ◽  
Paolo Ricci ◽  
Luigi Muratori ◽  
...  

Abstract Our aim was to investigate whether host genetic factors are involved in the onset of hepatitis C virus (HCV)-related mixed cryoglobulinemia (MC). We studied 25 consecutive patients presenting with a full-blown clinical picture of MC by physical examination, blood chemistry, assessment of cryoglobulins and their composition, nonorgan-specific autoantibodies, antibodies to HCV, serum HCV RNA, and HLA polymorphism. Biopsies of liver, bone marrow, and minor salivary glands were also performed in a number of patients. HLA results were compared with those of normal controls and patients with chronic HCV infection without MC and negative for autoimmune phenomena (pathological controls). Type II MC was found in 14 of 25 patients (56%), and type III MC was found in the remaining 11 (44%). All patients were positive for antibodies to HCV and/or serum HCV RNA. HLA-B8 was found in 40% (10 of 25) of patients compared with 10.1% (38 of 377) of normal controls (P = .00003, Pcorrected = .0005, relative risk [RR] 5.9) and 6.7% (2 of 30) of pathological controls (P = .007, Pcorrected = not significant). As for class II HLA molecules, only DR3 was significantly more frequent in MC patients (40%, 10 of 25) than in normal controls (15.1%, 57 of 377; P = .003, Pcorrected= .03, RR 3.7). Odds ratio (OR) for the risk of developing MC was calculated in patients positive for B8 and/or DR3, and the highest OR (8.2) was observed in individuals possessing both. The results suggest that the development of HCV-related MC is associated with HLA-B8 and DR3 markers.


Sign in / Sign up

Export Citation Format

Share Document